Skip to main content
SpringerLink
Log in

Is RAS blockade routinely indicated in hypertensive kidney transplant patients?

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

There is a high incidence of hypertension after kidney transplantation, which has been associated with the development of left ventricular hypertrophy, an increased risk for acute rejection, lower graft survival, and increased mortality. The pathogenesis of post-transplant hypertension is multifactorial, and therefore optimum therapy for it is not clearly defined. Historically, use of renin-angiotensin system (RAS) blockade in post-transplant hypertension has been limited given concerns of inducing worsening allograft function. Recent data demonstrated that subjects with post-transplant hypertension can be treated effectively with RAS blockers, and that these agents may offer significant additional benefits beyond blood pressure control. Review of the literature suggests that RAS blockers should be considered as useful agents for treatment of post-transplant hypertension not due to transplant renal artery stenosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Peeters J, Roels L, Vanrenterghem Y: Chronic renal allograft failure: clinical overview. The Leuven Collaborative Group for Transplantation. Kidney Int Suppl 1995, 52:S97–101.

    PubMed  CAS  Google Scholar 

  2. Artz MA, Hilbrands LB, Borm G, et al.: Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant 2004, 19:2852–2857.

    Article  PubMed  CAS  Google Scholar 

  3. Raine AE: Does antihypertensive therapy modify chronic allograft failure? Kidney Int Suppl 1995, 52:S107–111.

    PubMed  CAS  Google Scholar 

  4. Kasiske BL, Anjum S, Shah R, et al.: Hypertension after kidney transplantation. Am J Kidney Dis 2004, 43:1071–1081.

    Article  PubMed  Google Scholar 

  5. Sorof JM, Sullivan EK, Tejani A, Portman RJ: Antihypertensive medication and renal allograft failure: a North American Pediatric Renal Transplant Cooperative Study report. J Am Soc Nephrol 1999, 10:1324–1330.

    PubMed  CAS  Google Scholar 

  6. Sanders CE Jr, Curtis JJ: Role of hypertension in chronic renal allograft dysfunction. Kidney Int Suppl 1995, 52:S43–47.

    PubMed  Google Scholar 

  7. Oliveras A, Vazquez S, Hurtado S, et al.: Ambulatory blood pressure monitoring in renal transplant patients: modifiable parameters after active antihypertensive treatment. Transplant Proc 2004, 36:1352–1354.

    Article  PubMed  CAS  Google Scholar 

  8. Budde K, Waiser J, Fritsche L, et al.: Hypertension in patients after renal transplantation. Transplant Proc 1997, 29:209–211.

    Article  PubMed  CAS  Google Scholar 

  9. Lipkin GW, Tucker B, Giles M, Raine AE: Ambulatory blood pressure and left ventricular mass in cyclosporin-and non-cyclosporin-treated renal transplant recipients. J Hypertens 1993, 11:439–442.

    Article  PubMed  CAS  Google Scholar 

  10. McNally PG, Feehally J: Pathophysiology of cyclosporin A nephrotoxicity: experimental and clinical observations. Nephrol Dial Transplant 1992, 7:791–804.

    PubMed  CAS  Google Scholar 

  11. Bruno S, Remuzzi G, Ruggenenti P: Transplant renal artery stenosis. J Am Soc Nephrol 2004, 15:134–141.

    Article  PubMed  Google Scholar 

  12. Conte G, Dal Canton A, Sabbatini M, et al.: Acute cyclosporine renal dysfunction reversed by dopamine infusion in healthy subjects. Kidney Int 1989, 36:1086–1092.

    Article  PubMed  CAS  Google Scholar 

  13. Lee DB: Cyclosporine and the renin-angiotensin axis. Kidney Int 1997, 52:248–260.

    Article  PubMed  CAS  Google Scholar 

  14. Khanna A, Kapur S, Sharma V, et al.: In vivo hyperex-pression of transforming growth factor-beta1 in mice: stimulation by cyclosporine. Transplantation 1997, 63:1037–1039.

    Article  PubMed  CAS  Google Scholar 

  15. Little DM, Haynes LD, Alam T, et al.: Does transforming growth factor beta 1 play a role in the pathogenesis of chronic allograft rejection? Transplant Int 1999, 12:393–401.

    Article  CAS  Google Scholar 

  16. Crowley SD, Tharaux PL, Audoly LP, Coffman TM: Exploring type I angiotensin (AT1) receptor functions through gene targeting. Acta Physiol Scand 2004, 181:561–570.

    Article  PubMed  CAS  Google Scholar 

  17. Cosio FG, Pelletier RP, Pesavento TE, et al.: Elevated blood pressure predicts the risk of acute rejection in renal allograft recipients. Kidney Int 2001, 59:1158–1164.

    Article  PubMed  CAS  Google Scholar 

  18. Cosio FG, Pelletier RP, Sedmak DD, et al.: Renal allograft survival following acute rejection correlates with blood pressure levels and histopathology. Kidney Int 1999, 56:1912–1919.

    Article  PubMed  CAS  Google Scholar 

  19. Opelz G, Wujciak T, Ritz E: Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998, 53:217–222.

    Article  PubMed  CAS  Google Scholar 

  20. Mange KC, Cizman B, Joffe M, Feldman HI: Arterial hypertension and renal allograft survival. JAMA 2000, 283:633–638.

    Article  PubMed  CAS  Google Scholar 

  21. Mimran A, Ribstein J: Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases. Am J Hypertens 1994, 7(9 Pt 2):73S–81S.

    PubMed  CAS  Google Scholar 

  22. Tutone VK, Mark PB, Stewart GA, et al.: Hypertension, antihypertensive agents and outcomes following renal transplantation. Clin Transplant 2005, 19:181–192.

    Article  PubMed  CAS  Google Scholar 

  23. Ruggenenti P, Perico N, Mosconi L, et al.: Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993, 43:706–711.

    Article  PubMed  CAS  Google Scholar 

  24. Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE: Enalapril-associated anemia in renal transplant recipients treated for hypertension. Am J Kidney Dis 1991, 17:199–205.

    PubMed  CAS  Google Scholar 

  25. Curtis JJ, Luke RG, Whelchel JD, et al.: Inhibition of angiotensin-converting enzyme in renal-transplant recipients with hypertension. N Engl J Med 1983, 308:377–381.

    Article  PubMed  CAS  Google Scholar 

  26. Andrés A, Morales E, Morales JM, et al.: Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study. Transplant Proc 2006, 38:2419–2423.

    Article  PubMed  CAS  Google Scholar 

  27. Kornerup HJ, Pedersen EB, Fjeldborg O: Kidney transplant artery stenosis. Interrelationship between blood pressure, kidney function, renin-aldosterone system and body sodium content. Proc Eur Dial Transplant Assoc 1977, 14:377–385.

    PubMed  CAS  Google Scholar 

  28. del Castillo D, Campistol JM, Guirado L, et al.: Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int Suppl 1998, 68:S135–139.

    Article  PubMed  Google Scholar 

  29. Curtis JJ, Laskow DA, Jones PA, et al.: Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients. J Am Soc Nephrol 1993, 3:1570–1574.

    PubMed  CAS  Google Scholar 

  30. Shihab FS, Bennett WM, Tanner AM, Andoh TF: Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997, 52:660–673.

    Article  PubMed  CAS  Google Scholar 

  31. Dragun D, Muller DN, Brasen JH, et al.: Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005, 352:558–569.

    Article  PubMed  CAS  Google Scholar 

  32. Calvino J, Lens XM, Romero R, Sanchez-Guisande D: Long-term anti-proteinuric effect of losartan in renal transplant recipients treated for hypertension. Nephrol Dial Transplant 2000, 15:82–86.

    Article  PubMed  CAS  Google Scholar 

  33. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860.

    Article  PubMed  CAS  Google Scholar 

  34. Bochicchio T, Sandoval G, Ron O, et al.: Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives. Kidney Int 1990, 38:873–879.

    Article  PubMed  CAS  Google Scholar 

  35. Mason J, Muller-Schweinitzer E, Dupont M, et al.: Cyclosporine and the renin-angiotensin system. Kidney Int Suppl 1991, 32:S28–32.

    PubMed  CAS  Google Scholar 

  36. Border WA, Noble NA: Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998, 31(1 Pt 2):181–188.

    PubMed  CAS  Google Scholar 

  37. Kagami S, Kuhara T, Okada K, et al.: Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 1997, 51:664–671.

    Article  PubMed  CAS  Google Scholar 

  38. Shihab FS, Tanner AM, Shao Y, Weffer MI: Expression of TGF-beta 1 and matrix proteins is elevated in rats with chronic rejection. Kidney Int 1996, 50:1904–1913.

    Article  PubMed  CAS  Google Scholar 

  39. Sharma K, Eltayeb BO, McGowan TA, et al.: Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999, 34:818–823. [Published erratum appears in Am J Kidney Dis 2000, 35:572.]

    PubMed  CAS  Google Scholar 

  40. Campistol JM, Inigo P, Jimenez W, et al.: Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999, 56:714–719.

    Article  PubMed  CAS  Google Scholar 

  41. Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359:1004–1010.

    Article  PubMed  CAS  Google Scholar 

  42. Yusuf S, Sleight P, Pogue, J, et al.: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992, 327:685–691.

    Article  Google Scholar 

  43. Heinze G, Mitterbauer C, Regele H, et al.: Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patients and graft survival after renal transplantation. J Am Soc Nephrol 2006, 17:889–899.

    Article  PubMed  CAS  Google Scholar 

  44. Hausberg M, Barenbrock M, Hohage H, et al.: ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999, 33:862–868.

    PubMed  Google Scholar 

  45. Midtvedt K, Hartmann A, Foss A, et al.: Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001, 72:1787–1792.

    Article  PubMed  CAS  Google Scholar 

  46. Hadjigavriel M, Kyriakides G: Efficacy and safety of losartan in renal transplant recipients. Transplant Proc 1999, 31:3300–3301.

    Article  PubMed  CAS  Google Scholar 

  47. Premasathian NC, Muehrer R, Brazy PC, et al.: Blood pressure control in kidney transplantation: therapeutic implications. J Hum Hypertens 2004, 18:871–877.

    Article  PubMed  CAS  Google Scholar 

  48. Lorenz M, Billensteiner E, Bodingbauer M, et al.: The effect of ACE inhibitor and angiotensin II blocker therapy on early posttransplant kidney graft function. Am J Kidney Dis 2004, 43:1065–1070.

    Article  PubMed  CAS  Google Scholar 

  49. Heinze G, Collins S, Benedict MA, et al.: The association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use during postischemic acute transplant failure and renal allograft survival. Transplantation 2006, 82:1441–1448.

    Article  PubMed  CAS  Google Scholar 

  50. Traindl O, Falger S, Reading S, et al.: The effects of lisinopril on renal function in proteinuric renal transplant recipients. Transplantation 1993, 55:1309–1313.

    Article  PubMed  CAS  Google Scholar 

  51. el-Agroudy AE, Hassan NA, Foda MA, et al.: Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. Am J Nephrol 2003, 23:300–306.

    Article  PubMed  CAS  Google Scholar 

  52. Amuchastegui SC, Azzollini N, Mister M, et al.: Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 1998, 9:1948–1955.

    PubMed  CAS  Google Scholar 

  53. Benediktsson H, Chea R, Davidoff A, Paul LC: Antihypertensive drug treatment in chronic renal allograft rejection in the rat. Effect on structure and function. Transplantation 1996, 62:1634–1642.

    Article  PubMed  CAS  Google Scholar 

  54. Lin J, Valeri AM, Markowitz GS, et al.: Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 2002, 73:783–788.

    Article  PubMed  CAS  Google Scholar 

  55. Philipp T, Legendre C, Geiger H, et al.: Study on the Evaluation of Candesartan cilexetil after Renal Transplantation (SECRET-Study) [abstract]. Available at: http://www.egms.de/en/meetings/hoch2004/04hoch126.shtml. Accessed July 26, 2007.

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, University of Maryland Medical Center, 22 South Greene Street, Room N3W143, Baltimore, MD, 21201, USA

    Daniel J. Salzberg

Authors
  1. Daniel J. Salzberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel J. Salzberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Salzberg, D.J. Is RAS blockade routinely indicated in hypertensive kidney transplant patients?. Current Science Inc 9, 422–429 (2007). https://doi.org/10.1007/s11906-007-0077-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-007-0077-4

Keywords

Search

Navigation